Notably, PROTACs degrading CDK4/6 have shown greater efficacy than traditional CDK4/6 kinase inhibitors in RB1-deficient cancer models, yet the mechanism behind this increased effectiveness remains to be clarified42,43. This evidence concerns the gene RB1 and cancer.